Veeva Systems Inc.
Veeva Systems Inc. VEEV Peers
See (VEEV) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VEEV | $279.78 | +0.27% | 45.6B | 59.28 | $4.72 | N/A |
| GEHC | $70.54 | -1.38% | 32.3B | 14.73 | $4.79 | +0.18% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | +0.18% |
| DOCS | $52.06 | +0.23% | 9.8B | 46.90 | $1.11 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $100.61 | -0.37% | 8.7B | 92.30 | $1.09 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
| BTSGU | $83.87 | +2.49% | 4.2B | N/A | N/A | N/A |
| BTSG | $23.81 | +1.75% | 4.1B | 88.19 | $0.27 | N/A |
| ONEM | $16.47 | N/A | 3.4B | -7.77 | -$2.12 | N/A |
Stock Comparison
VEEV vs GEHC Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, GEHC has a market cap of 32.3B. Regarding current trading prices, VEEV is priced at $279.78, while GEHC trades at $70.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas GEHC's P/E ratio is 14.73. In terms of profitability, VEEV's ROE is +0.13%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, VEEV is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs GEHCV Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, VEEV is priced at $279.78, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas GEHCV's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, VEEV is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs DOCS Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, DOCS has a market cap of 9.8B. Regarding current trading prices, VEEV is priced at $279.78, while DOCS trades at $52.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas DOCS's P/E ratio is 46.90. In terms of profitability, VEEV's ROE is +0.13%, compared to DOCS's ROE of +0.22%. Regarding short-term risk, VEEV is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SGFY Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, VEEV is priced at $279.78, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SGFY's P/E ratio is 70.91. In terms of profitability, VEEV's ROE is +0.13%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, VEEV is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs HQY Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, HQY has a market cap of 8.7B. Regarding current trading prices, VEEV is priced at $279.78, while HQY trades at $100.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas HQY's P/E ratio is 92.30. In terms of profitability, VEEV's ROE is +0.13%, compared to HQY's ROE of +0.05%. Regarding short-term risk, VEEV is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs RCM Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, RCM has a market cap of 6B. Regarding current trading prices, VEEV is priced at $279.78, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas RCM's P/E ratio is -102.21. In terms of profitability, VEEV's ROE is +0.13%, compared to RCM's ROE of -0.02%. Regarding short-term risk, VEEV is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs BTSGU Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, BTSGU has a market cap of 4.2B. Regarding current trading prices, VEEV is priced at $279.78, while BTSGU trades at $83.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas BTSGU's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, VEEV is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs BTSG Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, BTSG has a market cap of 4.1B. Regarding current trading prices, VEEV is priced at $279.78, while BTSG trades at $23.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas BTSG's P/E ratio is 88.19. In terms of profitability, VEEV's ROE is +0.13%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, VEEV is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs ONEM Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, VEEV is priced at $279.78, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas ONEM's P/E ratio is -7.77. In terms of profitability, VEEV's ROE is +0.13%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, VEEV is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs PRVA Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, PRVA has a market cap of 2.8B. Regarding current trading prices, VEEV is priced at $279.78, while PRVA trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas PRVA's P/E ratio is 189.50. In terms of profitability, VEEV's ROE is +0.13%, compared to PRVA's ROE of +0.02%. Regarding short-term risk, VEEV is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs WGS Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, WGS has a market cap of 2B. Regarding current trading prices, VEEV is priced at $279.78, while WGS trades at $71.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas WGS's P/E ratio is -51.24. In terms of profitability, VEEV's ROE is +0.13%, compared to WGS's ROE of -0.17%. Regarding short-term risk, VEEV is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs PINC Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, PINC has a market cap of 1.9B. Regarding current trading prices, VEEV is priced at $279.78, while PINC trades at $22.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas PINC's P/E ratio is 22.53. In terms of profitability, VEEV's ROE is +0.13%, compared to PINC's ROE of +0.03%. Regarding short-term risk, VEEV is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs CERT Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CERT has a market cap of 1.8B. Regarding current trading prices, VEEV is priced at $279.78, while CERT trades at $11.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CERT's P/E ratio is -567.75. In terms of profitability, VEEV's ROE is +0.13%, compared to CERT's ROE of -0.00%. Regarding short-term risk, VEEV is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs PGNY Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, PGNY has a market cap of 1.8B. Regarding current trading prices, VEEV is priced at $279.78, while PGNY trades at $21.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas PGNY's P/E ratio is 37.70. In terms of profitability, VEEV's ROE is +0.13%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, VEEV is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs NXGN Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, VEEV is priced at $279.78, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas NXGN's P/E ratio is -266.00. In terms of profitability, VEEV's ROE is +0.13%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, VEEV is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SDGR Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SDGR has a market cap of 1.6B. Regarding current trading prices, VEEV is priced at $279.78, while SDGR trades at $21.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SDGR's P/E ratio is -8.22. In terms of profitability, VEEV's ROE is +0.13%, compared to SDGR's ROE of -0.45%. Regarding short-term risk, VEEV is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs PHR Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, PHR has a market cap of 1.5B. Regarding current trading prices, VEEV is priced at $279.78, while PHR trades at $24.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas PHR's P/E ratio is -33.08. In terms of profitability, VEEV's ROE is +0.13%, compared to PHR's ROE of -0.23%. Regarding short-term risk, VEEV is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs OMCL Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, OMCL has a market cap of 1.4B. Regarding current trading prices, VEEV is priced at $279.78, while OMCL trades at $30.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas OMCL's P/E ratio is 66.02. In terms of profitability, VEEV's ROE is +0.13%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, VEEV is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs GDRX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, GDRX has a market cap of 1.4B. Regarding current trading prices, VEEV is priced at $279.78, while GDRX trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas GDRX's P/E ratio is 56.00. In terms of profitability, VEEV's ROE is +0.13%, compared to GDRX's ROE of +0.07%. Regarding short-term risk, VEEV is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs AGTI Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, VEEV is priced at $279.78, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas AGTI's P/E ratio is -71.79. In terms of profitability, VEEV's ROE is +0.13%, compared to AGTI's ROE of -0.01%. Regarding short-term risk, VEEV is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs TDOC Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, VEEV is priced at $279.78, while TDOC trades at $6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas TDOC's P/E ratio is -1.17. In terms of profitability, VEEV's ROE is +0.13%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, VEEV is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs TXG Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, TXG has a market cap of 1.1B. Regarding current trading prices, VEEV is priced at $279.78, while TXG trades at $9.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas TXG's P/E ratio is -6.96. In terms of profitability, VEEV's ROE is +0.13%, compared to TXG's ROE of -0.22%. Regarding short-term risk, VEEV is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs NUTX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, NUTX has a market cap of 931M. Regarding current trading prices, VEEV is priced at $279.78, while NUTX trades at $167.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas NUTX's P/E ratio is 13.58. In terms of profitability, VEEV's ROE is +0.13%, compared to NUTX's ROE of +0.71%. Regarding short-term risk, VEEV is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs EVH Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, EVH has a market cap of 875.2M. Regarding current trading prices, VEEV is priced at $279.78, while EVH trades at $7.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas EVH's P/E ratio is -6.11. In terms of profitability, VEEV's ROE is +0.13%, compared to EVH's ROE of -0.11%. Regarding short-term risk, VEEV is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs HSTM Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, HSTM has a market cap of 854.7M. Regarding current trading prices, VEEV is priced at $279.78, while HSTM trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas HSTM's P/E ratio is 44.44. In terms of profitability, VEEV's ROE is +0.13%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, VEEV is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SLP Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SLP has a market cap of 640.4M. Regarding current trading prices, VEEV is priced at $279.78, while SLP trades at $31.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SLP's P/E ratio is 88.46. In terms of profitability, VEEV's ROE is +0.13%, compared to SLP's ROE of +0.04%. Regarding short-term risk, VEEV is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs CTEV Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CTEV has a market cap of 630.7M. Regarding current trading prices, VEEV is priced at $279.78, while CTEV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CTEV's P/E ratio is -0.53. In terms of profitability, VEEV's ROE is +0.13%, compared to CTEV's ROE of -5.18%. Regarding short-term risk, VEEV is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs MPLN-WT Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, VEEV is priced at $279.78, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MPLN-WT's ROE of -5.18%. Regarding short-term risk, VEEV is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs ACCD Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, VEEV is priced at $279.78, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas ACCD's P/E ratio is -3.08. In terms of profitability, VEEV's ROE is +0.13%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, VEEV is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs CCLDP Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CCLDP has a market cap of 566.6M. Regarding current trading prices, VEEV is priced at $279.78, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CCLDP's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CCLDP's ROE of +0.21%. Regarding short-term risk, VEEV is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SHCR Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, VEEV is priced at $279.78, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SHCR's P/E ratio is -3.76. In terms of profitability, VEEV's ROE is +0.13%, compared to SHCR's ROE of -0.24%. Regarding short-term risk, VEEV is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SLGCW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, VEEV is priced at $279.78, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, VEEV's ROE is +0.13%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, VEEV is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs SLGC Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, VEEV is priced at $279.78, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SLGC's P/E ratio is -3.04. In terms of profitability, VEEV's ROE is +0.13%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, VEEV is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs MPLN Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, VEEV is priced at $279.78, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas MPLN's P/E ratio is -0.23. In terms of profitability, VEEV's ROE is +0.13%, compared to MPLN's ROE of -5.18%. Regarding short-term risk, VEEV is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs TBRG Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, TBRG has a market cap of 359.5M. Regarding current trading prices, VEEV is priced at $279.78, while TBRG trades at $23.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas TBRG's P/E ratio is -19.61. In terms of profitability, VEEV's ROE is +0.13%, compared to TBRG's ROE of -0.10%. Regarding short-term risk, VEEV is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs DH Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, DH has a market cap of 355.3M. Regarding current trading prices, VEEV is priced at $279.78, while DH trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas DH's P/E ratio is -0.75. In terms of profitability, VEEV's ROE is +0.13%, compared to DH's ROE of -1.07%. Regarding short-term risk, VEEV is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs SPOK Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SPOK has a market cap of 333.3M. Regarding current trading prices, VEEV is priced at $279.78, while SPOK trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SPOK's P/E ratio is 21.04. In terms of profitability, VEEV's ROE is +0.13%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, VEEV is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs NRC Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, NRC has a market cap of 308.2M. Regarding current trading prices, VEEV is priced at $279.78, while NRC trades at $13.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas NRC's P/E ratio is 13.26. In terms of profitability, VEEV's ROE is +0.13%, compared to NRC's ROE of +0.71%. Regarding short-term risk, VEEV is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs TRHC Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, VEEV is priced at $279.78, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas TRHC's P/E ratio is -4.27. In terms of profitability, VEEV's ROE is +0.13%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, VEEV is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs HCAT Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, HCAT has a market cap of 263.8M. Regarding current trading prices, VEEV is priced at $279.78, while HCAT trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas HCAT's P/E ratio is -3.30. In terms of profitability, VEEV's ROE is +0.13%, compared to HCAT's ROE of -0.20%. Regarding short-term risk, VEEV is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs SMFR Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, VEEV is priced at $279.78, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SMFR's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, VEEV is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs OPRX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, OPRX has a market cap of 224.2M. Regarding current trading prices, VEEV is priced at $279.78, while OPRX trades at $12.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas OPRX's P/E ratio is -14.43. In terms of profitability, VEEV's ROE is +0.13%, compared to OPRX's ROE of -0.13%. Regarding short-term risk, VEEV is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs SOPH Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SOPH has a market cap of 200.5M. Regarding current trading prices, VEEV is priced at $279.78, while SOPH trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SOPH's P/E ratio is -3.00. In terms of profitability, VEEV's ROE is +0.13%, compared to SOPH's ROE of -0.63%. Regarding short-term risk, VEEV is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs EUDA Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, EUDA has a market cap of 135.6M. Regarding current trading prices, VEEV is priced at $279.78, while EUDA trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas EUDA's P/E ratio is -6.76. In terms of profitability, VEEV's ROE is +0.13%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, VEEV is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs CPSI Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, VEEV is priced at $279.78, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CPSI's P/E ratio is -183.80. In terms of profitability, VEEV's ROE is +0.13%, compared to CPSI's ROE of -0.18%. Regarding short-term risk, VEEV is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs AUGX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, VEEV is priced at $279.78, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas AUGX's P/E ratio is -4.99. In terms of profitability, VEEV's ROE is +0.13%, compared to AUGX's ROE of -1.13%. Regarding short-term risk, VEEV is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SY Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SY has a market cap of 111.7M. Regarding current trading prices, VEEV is priced at $279.78, while SY trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SY's P/E ratio is -1.06. In terms of profitability, VEEV's ROE is +0.13%, compared to SY's ROE of -0.26%. Regarding short-term risk, VEEV is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs AMWL Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, AMWL has a market cap of 105.6M. Regarding current trading prices, VEEV is priced at $279.78, while AMWL trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas AMWL's P/E ratio is -0.66. In terms of profitability, VEEV's ROE is +0.13%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, VEEV is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs CCLDO Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CCLDO has a market cap of 87M. Regarding current trading prices, VEEV is priced at $279.78, while CCLDO trades at $20.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CCLDO's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CCLDO's ROE of +0.21%. Regarding short-term risk, VEEV is less volatile compared to CCLDO. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs CCLD Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CCLD has a market cap of 85.5M. Regarding current trading prices, VEEV is priced at $279.78, while CCLD trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CCLD's P/E ratio is -9.18. In terms of profitability, VEEV's ROE is +0.13%, compared to CCLD's ROE of +0.21%. Regarding short-term risk, VEEV is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs FORA Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, FORA has a market cap of 64.3M. Regarding current trading prices, VEEV is priced at $279.78, while FORA trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas FORA's P/E ratio is -17.17. In terms of profitability, VEEV's ROE is +0.13%, compared to FORA's ROE of -0.13%. Regarding short-term risk, VEEV is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs BEAT Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, BEAT has a market cap of 57.5M. Regarding current trading prices, VEEV is priced at $279.78, while BEAT trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas BEAT's P/E ratio is -2.30. In terms of profitability, VEEV's ROE is +0.13%, compared to BEAT's ROE of -3.58%. Regarding short-term risk, VEEV is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs BEATW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, BEATW has a market cap of 53.2M. Regarding current trading prices, VEEV is priced at $279.78, while BEATW trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas BEATW's P/E ratio is -1.07. In terms of profitability, VEEV's ROE is +0.13%, compared to BEATW's ROE of -3.58%. Regarding short-term risk, VEEV is more volatile compared to BEATW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SNCE Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, VEEV is priced at $279.78, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SNCE's P/E ratio is -0.27. In terms of profitability, VEEV's ROE is +0.13%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, VEEV is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs AKLI Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, VEEV is priced at $279.78, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas AKLI's P/E ratio is -0.71. In terms of profitability, VEEV's ROE is +0.13%, compared to AKLI's ROE of -0.38%. Regarding short-term risk, VEEV is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SHLT Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, VEEV is priced at $279.78, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SHLT's P/E ratio is -3.87. In terms of profitability, VEEV's ROE is +0.13%, compared to SHLT's ROE of -0.09%. Regarding short-term risk, VEEV is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs SHCRW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, VEEV is priced at $279.78, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to SHCRW's ROE of -0.24%. Regarding short-term risk, VEEV is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs MGRX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, MGRX has a market cap of 23.8M. Regarding current trading prices, VEEV is priced at $279.78, while MGRX trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas MGRX's P/E ratio is -0.47. In terms of profitability, VEEV's ROE is +0.13%, compared to MGRX's ROE of -0.73%. Regarding short-term risk, VEEV is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs RNLX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, VEEV is priced at $279.78, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas RNLX's P/E ratio is -0.33. In terms of profitability, VEEV's ROE is +0.13%, compared to RNLX's ROE of +2.93%. Regarding short-term risk, VEEV is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs STRM Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, STRM has a market cap of 22.4M. Regarding current trading prices, VEEV is priced at $279.78, while STRM trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas STRM's P/E ratio is -2.05. In terms of profitability, VEEV's ROE is +0.13%, compared to STRM's ROE of -0.68%. Regarding short-term risk, VEEV is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs LIFW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, VEEV is priced at $279.78, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas LIFW's P/E ratio is -0.02. In terms of profitability, VEEV's ROE is +0.13%, compared to LIFW's ROE of -3.08%. Regarding short-term risk, VEEV is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs VSEEW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, VSEEW has a market cap of 20.1M. Regarding current trading prices, VEEV is priced at $279.78, while VSEEW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas VSEEW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, VEEV is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs VSEE Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, VSEE has a market cap of 19.7M. Regarding current trading prices, VEEV is priced at $279.78, while VSEE trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas VSEE's P/E ratio is -14.00. In terms of profitability, VEEV's ROE is +0.13%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, VEEV is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs BFRG Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, BFRG has a market cap of 16M. Regarding current trading prices, VEEV is priced at $279.78, while BFRG trades at $1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas BFRG's P/E ratio is -2.12. In terms of profitability, VEEV's ROE is +0.13%, compared to BFRG's ROE of -1.63%. Regarding short-term risk, VEEV is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs BBLN Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, VEEV is priced at $279.78, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas BBLN's P/E ratio is -0.04. In terms of profitability, VEEV's ROE is +0.13%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, VEEV is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs INOV Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, INOV has a market cap of 13.9M. Regarding current trading prices, VEEV is priced at $279.78, while INOV trades at $31.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas INOV's P/E ratio is 16.68. In terms of profitability, VEEV's ROE is +0.13%, compared to INOV's ROE of +0.03%. Regarding short-term risk, VEEV is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs ONMD Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, ONMD has a market cap of 12.2M. Regarding current trading prices, VEEV is priced at $279.78, while ONMD trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas ONMD's P/E ratio is -1.18. In terms of profitability, VEEV's ROE is +0.13%, compared to ONMD's ROE of +0.60%. Regarding short-term risk, VEEV is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs SCNX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, SCNX has a market cap of 11.5M. Regarding current trading prices, VEEV is priced at $279.78, while SCNX trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas SCNX's P/E ratio is 1.32. In terms of profitability, VEEV's ROE is +0.13%, compared to SCNX's ROE of +0.19%. Regarding short-term risk, VEEV is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs MSPR Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, MSPR has a market cap of 10.2M. Regarding current trading prices, VEEV is priced at $279.78, while MSPR trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas MSPR's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MSPR's ROE of -3.08%. Regarding short-term risk, VEEV is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs ETAO Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, VEEV is priced at $279.78, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas ETAO's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, VEEV is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs HLTH Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, VEEV is priced at $279.78, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas HLTH's P/E ratio is -0.02. In terms of profitability, VEEV's ROE is +0.13%, compared to HLTH's ROE of -0.88%. Regarding short-term risk, VEEV is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs OTRK Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, OTRK has a market cap of 6.2M. Regarding current trading prices, VEEV is priced at $279.78, while OTRK trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas OTRK's P/E ratio is -0.09. In terms of profitability, VEEV's ROE is +0.13%, compared to OTRK's ROE of -1.76%. Regarding short-term risk, VEEV is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs ZCMD Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, ZCMD has a market cap of 6M. Regarding current trading prices, VEEV is priced at $279.78, while ZCMD trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas ZCMD's P/E ratio is -9.67. In terms of profitability, VEEV's ROE is +0.13%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, VEEV is more volatile compared to ZCMD. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs EUDAW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, EUDAW has a market cap of 5.5M. Regarding current trading prices, VEEV is priced at $279.78, while EUDAW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas EUDAW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, VEEV is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs UPH Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, VEEV is priced at $279.78, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas UPH's P/E ratio is -0.07. In terms of profitability, VEEV's ROE is +0.13%, compared to UPH's ROE of -1.05%. Regarding short-term risk, VEEV is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs PEARW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, VEEV is priced at $279.78, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas PEARW's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, VEEV is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs PEAR Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, VEEV is priced at $279.78, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas PEAR's P/E ratio is -0.08. In terms of profitability, VEEV's ROE is +0.13%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, VEEV is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs ACON Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, ACON has a market cap of 3.7M. Regarding current trading prices, VEEV is priced at $279.78, while ACON trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas ACON's P/E ratio is -0.56. In terms of profitability, VEEV's ROE is +0.13%, compared to ACON's ROE of -1.27%. Regarding short-term risk, VEEV is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs HCTI Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, HCTI has a market cap of 3.1M. Regarding current trading prices, VEEV is priced at $279.78, while HCTI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas HCTI's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to HCTI's ROE of +2.95%. Regarding short-term risk, VEEV is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs FOXO Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, FOXO has a market cap of 2.6M. Regarding current trading prices, VEEV is priced at $279.78, while FOXO trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas FOXO's P/E ratio is -0.05. In terms of profitability, VEEV's ROE is +0.13%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, VEEV is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs WGSWW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, WGSWW has a market cap of 2M. Regarding current trading prices, VEEV is priced at $279.78, while WGSWW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas WGSWW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, VEEV is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs WORX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, WORX has a market cap of 1.9M. Regarding current trading prices, VEEV is priced at $279.78, while WORX trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas WORX's P/E ratio is -0.59. In terms of profitability, VEEV's ROE is +0.13%, compared to WORX's ROE of -0.32%. Regarding short-term risk, VEEV is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs CMAX Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, VEEV is priced at $279.78, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CMAX's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, VEEV is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs ICCT Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, ICCT has a market cap of 1.3M. Regarding current trading prices, VEEV is priced at $279.78, while ICCT trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas ICCT's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to ICCT's ROE of -14.51%. Regarding short-term risk, VEEV is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs LIFWZ Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, VEEV is priced at $279.78, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to LIFWZ's ROE of -3.08%. Regarding short-term risk, VEEV is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs OTRKP Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, OTRKP has a market cap of 1M. Regarding current trading prices, VEEV is priced at $279.78, while OTRKP trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, VEEV's ROE is +0.13%, compared to OTRKP's ROE of -1.76%. Regarding short-term risk, VEEV is more volatile compared to OTRKP. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs KERNW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, VEEV is priced at $279.78, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas KERNW's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to KERNW's ROE of -2.22%. Regarding short-term risk, VEEV is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs KERN Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, VEEV is priced at $279.78, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas KERN's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to KERN's ROE of -2.22%. Regarding short-term risk, VEEV is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs MSPRZ Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, MSPRZ has a market cap of 103.4K. Regarding current trading prices, VEEV is priced at $279.78, while MSPRZ trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MSPRZ's ROE of -3.08%. Regarding short-term risk, VEEV is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs LIFWW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, VEEV is priced at $279.78, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas LIFWW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to LIFWW's ROE of -3.08%. Regarding short-term risk, VEEV is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs CMAXW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, VEEV is priced at $279.78, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CMAXW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, VEEV is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs ACONW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, ACONW has a market cap of 21.5K. Regarding current trading prices, VEEV is priced at $279.78, while ACONW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas ACONW's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to ACONW's ROE of -1.27%. Regarding short-term risk, VEEV is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs MSPRW Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, MSPRW has a market cap of 6.2K. Regarding current trading prices, VEEV is priced at $279.78, while MSPRW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas MSPRW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MSPRW's ROE of -3.08%. Regarding short-term risk, VEEV is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs UTRS Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, UTRS has a market cap of 888. Regarding current trading prices, VEEV is priced at $279.78, while UTRS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas UTRS's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, VEEV is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs NH Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, NH has a market cap of 0. Regarding current trading prices, VEEV is priced at $279.78, while NH trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas NH's P/E ratio is -0.12. In terms of profitability, VEEV's ROE is +0.13%, compared to NH's ROE of +0.35%. Regarding short-term risk, VEEV is less volatile compared to NH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs MSPRV Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, MSPRV has a market cap of 0. Regarding current trading prices, VEEV is priced at $279.78, while MSPRV trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas MSPRV's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MSPRV's ROE of -3.08%. Regarding short-term risk, VEEV is less volatile compared to MSPRV. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.
VEEV vs CERN Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CERN has a market cap of 0. Regarding current trading prices, VEEV is priced at $279.78, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CERN's P/E ratio is 55.84. In terms of profitability, VEEV's ROE is +0.13%, compared to CERN's ROE of +0.14%. Regarding short-term risk, VEEV is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs CNVY Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, CNVY has a market cap of 0. Regarding current trading prices, VEEV is priced at $279.78, while CNVY trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas CNVY's P/E ratio is -71.50. In terms of profitability, VEEV's ROE is +0.13%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, VEEV is more volatile compared to CNVY. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.
VEEV vs MTBCO Comparison
VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VEEV stands at 45.6B. In comparison, MTBCO has a market cap of 0. Regarding current trading prices, VEEV is priced at $279.78, while MTBCO trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VEEV currently has a P/E ratio of 59.28, whereas MTBCO's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MTBCO's ROE of +0.21%. Regarding short-term risk, VEEV is more volatile compared to MTBCO. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.